Snapshot
Danaher Corp /De/ reported $5.95B of revenue in Q1 2026, up 3.7% year over year, with diluted EPS of $1.45 and an operating margin of 22.6%.
- Revenue
- $5.95B
- YoY growth
- +3.7%
- Diluted EPS
- $1.45
- Operating margin
- 22.6%
What management said
- •Our team executed well in a dynamic environment, leveraging the Danaher Business System to accelerate innovation, drive productivity gains, and deliver better than expected adjusted EPS growth.
- •While we have limited direct revenue or supply chain exposure to the region, we're mindful of potential pressures from a sustained conflict.
- •With the strength of our balance sheet and robust free cash flow generation, we're well positioned for further capital deployment going forward.
- •Sales were $6 billion in the first quarter, and core revenue was up 0.5% year-over-year, with a 2.5% headwind from respiratory revenue partially offsetting 3% core revenue growth in the rest of the business.
- •Geographically, core revenue in developed markets were down slightly, with a mid-single-digit decline in North America and a mid-single-digit increase in Western Europe.
- •High growth markets were up low single digits with solid performance across most regions, including mid-single digit growth in China.
- •In China, better than expected growth in biotechnology and life sciences more than offset the expected high single-digit decline in diagnostics, which continued to be impacted by volume-based procurement and reimbursement policy changes.
- •Adjusted diluted net earnings per common share of $2.06 were up 9.5% year-over-year.
- •We generated $1.1 billion of free cash flow in the quarter, resulting in a free cash flow to net income conversion ratio of 105%.
- •Turning to capital deployment, in February, we announced our intention to acquire Masimo, a leading provider of mission critical pulse oximetry and patient monitoring solutions in acute care settings.
- •Now alongside M&A, we made significant progress on organic growth initiatives across Danaher, including new product introductions and strategic partnerships.
- •This closes a historical gap in Beckman's immunoassay test menu and positions Beckman to accelerate new placements, customer wins, and growth as the DxI 9000 rollout continues.
What went well
- •Adjusted diluted net earnings per share of $2.06 were up 9.5% year-over-year, ahead of expectations.
- •Bioprocessing core revenue grew high single digits, with high single-digit consumables growth driven by robust demand for commercialized therapies globally and notable strength in China.
- •Bioprocessing equipment order book posted over 30% year-over-year growth, the first positive year-over-year orders growth in nearly two years.
- •Life sciences and biotechnology accelerated in China, with overall China core revenue up mid-single digits and double-digit growth in the China bioprocessing business.
- •Adjusted operating profit margin of 30.2% was up 60 basis points, and the company generated $1.1 billion of free cash flow at a 105% free-cash-flow-to-net-income conversion ratio.
- •Diagnostics excluding China and respiratory delivered another quarter of mid-single-digit growth, with core molecular up mid-teens as Cepheid continued to take share.
What went wrong
- •A lighter than normal Q1 respiratory season at Cepheid created a 2.5% headwind to core revenue, partially offsetting 3% core growth in the rest of the business.
- •Core revenue in developed markets declined slightly, including a mid-single-digit decline in North America.
- •China diagnostics saw an expected high single-digit decline due to volume-based procurement and reimbursement policy changes.
- •Discovery and medical core revenue declined low single digits as academic customers faced funding constraints, hitting protein research instrumentation.
- •Management flagged rising oil prices and petrochemical derivative costs plus the Middle East conflict as potential indirect cost pressures to monitor.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Full-year core revenue growth | FY2026 | anchored to low end | low single digit first half, accelerating to mid-single digits exiting Q4 | Reaffirmed |
| Core revenue growth | Q2 2026 | — | Sequential improvement from Q1; low single digits in first half | New |
| First-half earnings growth | H1 2026 | — | Mid- to high single-digit earnings growth | New |
| Bioprocessing equipment revenue | FY2026 | down double digits in prior year | Assumes flat on equipment | Improved |
| China diagnostics VBP headwind | FY2026 | — | $75 million to $100 million headwind | Validated |
| Masimo accretion / ROIC | Post-acquisition | — | Accretive to adjusted EPS in first full year; high single-digit ROIC by year five | Reaffirmed |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total core revenue | +0.5% | 2.5% respiratory headwind partially offset 3% core growth in the rest of the business. |
| Biotechnology segment core revenue | +7% | Bioprocessing grew high single digits on robust commercial therapy demand and China strength, while discovery and medical declined low single digits. |
| Bioprocessing equipment orders | >+30% | First positive year-over-year orders growth in nearly two years off a lighter comp, supported by capacity under-investment and reshoring dynamics. |
| Adjusted operating profit margin | +60 bps to 30.2% | Year-over-year cost savings more than offset the negative impact of lower respiratory revenue. |
| Adjusted diluted EPS | +9.5% to $2.06 | Cost savings and portfolio resilience drove growth despite softer respiratory revenue. |
| China core revenue | +mid-single digits | Better than expected biotechnology and life sciences growth more than offset the expected high single-digit diagnostics decline from VBP. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing equipment order recovery | down double digits prior year | Over 30% year-over-year order growth; guide assumes flat equipment | rising |
| China recovery | — | Mid-single-digit core growth, double-digit bioprocessing, life sciences reinvesting; diagnostics still pressured by VBP | rising |
| Respiratory normalization at Cepheid | — | Lighter than normal Q1 season; expects return to ~$1.8 billion endemic run rate | declining |
| Masimo acquisition | announced February | Process progressing well; expected to close later this year with cost and revenue synergies | rising |
| AI as a growth and productivity driver | — | Viewed as a tailwind via autonomous science demand and AI-enabled DBS efficiencies | rising |
| Life sciences stabilization | — | Broad stabilization with pockets of improvement; consumables expected to turn slightly positive for the full year | rising |
Q&A summary
What is driving the implied acceleration in core growth through the year across the segments?
Management said there is no change to the progression laid out in January, with all three needed factors playing out as expected or slightly better. Headwinds from China diagnostics, respiratory, and life sciences comps total about 300 basis points or more in the first half and essentially go away by year-end, supporting mid-single-digit growth in Q4 without assuming any end-market improvement.
Should the strong bioprocessing consumables and >30% equipment order book inform expectations for later this year and into 2027?
Consumables strength is expected to progress consistently through the year. The equipment order book reaffirms the expected year-over-year improvement; the guide assumes flat equipment after a double-digit decline last year. Orders can be lumpy due to customer readiness, but the 30% growth marker is supportive of the out years.
What is the strategic rationale and synergy potential of the Masimo acquisition?
Management framed it as a typical Danaher deal extending its acute-care diagnostics strategy alongside Radiometer, citing a premier pulse oximetry asset, secular growth, geographic complementarity (Masimo stronger in the U.S., Radiometer in Europe), and direct call-point synergies. The CFO outlined $125 million of cost synergies and about $50 million of revenue synergies by year five, accretive at all levels.
Why is the Q2 sequential margin step-down larger than in prior years?
The typical several-hundred-basis-point Q1-to-Q2 step down is driven by seasonal respiratory decline, with somewhat more FX impact given recent dollar moves. Given the Q1 beat, management is pulling some second-half growth investments forward into Q2, expecting mid- to high single-digit first-half earnings growth.
How is AI influencing customer spending and DBS productivity across the business?
Management views AI as a near- and long-term growth accelerator for pharma/biotech, driving incremental demand for automation, analytical instruments, and reagents through autonomous science, then flowing to bioprocessing and more sophisticated diagnostics. Internally, DBS and AI are increasingly synonymous, driving cycle-time and efficiency gains, though no specific cost or revenue targets were shared.
What is offsetting the lower respiratory number to allow holding the full-year diagnostics guide?
Continued share gains at Cepheid in the core business and new assay launches (Xpert GI, MVP), mid-single-digit growth in non-respiratory diagnostics ex-China, Beckman Coulter innovation including the DxI 9000, and validated assumptions around the $75 million to $100 million China VBP headwind with higher patient volumes.